Starpharma Holdings Ltd (AU:SPL) — Market Cap & Net Worth
Market Cap & Net Worth: Starpharma Holdings Ltd (SPL)
Starpharma Holdings Ltd (AU:SPL) has a market capitalization of $215.93 Million (AU$305.17 Million) as of May 6, 2026. Listed on the AU stock exchange, this Australia-based company holds position #16278 globally and #464 in its home market, demonstrating a -3.33% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Starpharma Holdings Ltd's stock price AU$0.73 by its total outstanding shares 420928435 (420.93 Million). Analyse SPL operating cash flow to see how efficiently the company converts income to cash.
Starpharma Holdings Ltd Market Cap History: 2015 to 2026
Starpharma Holdings Ltd's market capitalization history from 2015 to 2026. Data shows growth from $223.38 Million to $215.93 Million (0.07% CAGR).
Index Memberships
Starpharma Holdings Ltd is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Australia All Ordinaries
AORD
|
$1.96 Trillion | 0.01% | #285 of 495 |
Weight: Starpharma Holdings Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Starpharma Holdings Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Starpharma Holdings Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
21.83x
Starpharma Holdings Ltd's market cap is 21.83 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $215.93 Million | $4.57 Million | -$21.29 Million | 47.21x | N/A |
| 2017 | $405.05 Million | $3.65 Million | -$15.22 Million | 111.06x | N/A |
| 2018 | $352.93 Million | $4.96 Million | -$10.29 Million | 71.20x | N/A |
| 2019 | $360.38 Million | $2.72 Million | -$14.25 Million | 132.49x | N/A |
| 2020 | $466.11 Million | $6.03 Million | -$14.68 Million | 77.26x | N/A |
| 2021 | $399.10 Million | $1.80 Million | -$19.73 Million | 221.97x | N/A |
| 2022 | $163.81 Million | $4.68 Million | -$16.15 Million | 34.99x | N/A |
| 2023 | $50.63 Million | $2.94 Million | -$15.64 Million | 17.23x | N/A |
| 2024 | $32.76 Million | $8.29 Million | -$8.16 Million | 3.95x | N/A |
| 2025 | $107.22 Million | $4.91 Million | -$9.99 Million | 21.83x | N/A |
Competitor Companies of SPL by Market Capitalization
Companies near Starpharma Holdings Ltd in the global market cap rankings as of May 6, 2026.
Key companies related to Starpharma Holdings Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.67 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #364 globally with a market cap of $72.97 Billion USD.
- UCB SA (BR:UCB): Ranked #515 globally with a market cap of $51.41 Billion USD ( €43.97 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #570 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.67 Billion | $424.36 |
| #364 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.97 Billion | $702.27 |
| #515 | UCB SA | BR:UCB | $51.41 Billion | €231.00 |
| #570 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Starpharma Holdings Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Starpharma Holdings Ltd's market cap moved from $223.38 Million to $ 215.93 Million, with a yearly change of 0.07%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$215.93 Million | +101.39% |
| 2025 | AU$107.22 Million | +227.27% |
| 2024 | AU$32.76 Million | -35.29% |
| 2023 | AU$50.63 Million | -69.09% |
| 2022 | AU$163.81 Million | -58.96% |
| 2021 | AU$399.10 Million | -14.38% |
| 2020 | AU$466.11 Million | +29.34% |
| 2019 | AU$360.38 Million | +2.11% |
| 2018 | AU$352.93 Million | -12.87% |
| 2017 | AU$405.05 Million | +87.59% |
| 2016 | AU$215.93 Million | -3.33% |
| 2015 | AU$223.38 Million | -- |
End of Day Market Cap According to Different Sources
On May 6th, 2026 the market cap of Starpharma Holdings Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $215.93 Million USD |
| MoneyControl | $215.93 Million USD |
| MarketWatch | $215.93 Million USD |
| marketcap.company | $215.93 Million USD |
| Reuters | $215.93 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Starpharma Holdings Ltd
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally. The company's products include VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurr… Read more